Test Code ANCA2 Cytoplasmic Neutrophil Antibodies, Inflammatory Bowel Disease Panel, Serum
Specimen Required
Only orderable as part of a profile. For more information see IBDP2 / Inflammatory Bowel Disease Serology Panel, Serum.
Supplies: Sarstedt Aliquot Tube, 5 mL (T914)
Collection Container/Tube:
Preferred: Serum gel
Acceptable: Red top
Submission Container/Tube: Plastic vial
Specimen Volume: 1 mL Serum
Collection Instructions: Centrifuge and aliquot serum into a plastic vial.
Useful For
Measurement of antineutrophil cytoplastic antibodies as a part of a profile to aid in distinguishing between ulcerative colitis and Crohn disease in patients for whom the specific diagnosis is unclear based on endoscopic, pathologic, and imaging evaluations
This test is not useful for determining the extent of disease in patients with inflammatory bowel disease or determining the response to disease-specific therapy including surgical resection of diseased intestine.
Method Name
Only orderable as part of a profile. For more information see IBDP2 / Inflammatory Bowel Disease Serology Panel, Serum.
Indirect Immunofluorescent Assay (IFA)
Reporting Name
Cytoplasmic Neutrophilic Ab IBD, SSpecimen Type
SerumSpecimen Minimum Volume
Serum: 0.4 mL
Specimen Stability Information
| Specimen Type | Temperature | Time |
|---|---|---|
| Serum | Refrigerated (preferred) | 21 days |
| Frozen | 21 days |
Reference Values
Only orderable as part of a profile. For more information see IBDP2 / Inflammatory Bowel Disease Serology Panel, Serum.
Negative (not detectable)
Interpretation
The presence of antineutrophil cytoplasmic antibodies (ANCA) in the absence of IgA and IgG anti-Saccharomyces cerevisiae antibodies (ASCA) is consistent with the diagnosis of ulcerative colitis; the presence of IgA and IgG ASCA in the absence of ANCA is consistent with Crohn disease.
Clinical Reference
1. Rose NR, Mackay IR, eds. Inflammatory bowel diseases. In: The Autoimmune Diseases. Elsevier; 2008
2. Lichtenstein GR, Loftus EV, Afzali A, et al. ACG Clinical Guideline: Management of Crohn's Disease in Adults. Am J Gastroenterol. 2025;120(6):1225-1264
3. Rubin DT, Ananthakrishnan AN, Siegel CA, Barnes EL, Long MD. ACG Clinical Guideline Update: Ulcerative Colitis in Adults. AM J Gastroenterol. 2025;120(6):1187-1224
4. Clark C, Turner J. Diagnostic modalities for inflammatory bowel disease: Serologic markers and endoscopy. Surg Clin North Am. 2015;95(6):1123-1141
5. Zhou G, Song Y, Yang W, et al: ASCA, ANCA, ALCA and many more: Are they useful in the diagnosis of inflammatory bowel disease? Dig Dis. 2016;34(1-2):90-97
6. Sendid B, Cornu M, Cordier C, Bouckaert J, Colombel JF, Poulain D. From ASCA breakthrough in Crohn's disease and Candida albicans research to thirty years of investigations about their meaning in human health. Autoimmun Rev. 2024;23(2):103486
Day(s) Performed
Monday through FridayPerforming Laboratory
Mayo Clinic Laboratories in Rochester
Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
86036
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| ANCA2 | Cytoplasmic Neutrophilic Ab IBD, S | 17355-9 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| 610030 | Cytoplasmic Neutrophilic Ab IBD, S | 17355-9 |
| 614542 | ANCA2 Interpretation | 49308-0 |